NASDAQ:VCYT

Veracyte Stock Insider Trading

Healthcare > Biotechnology

Buy VCYT

*Your capital is at risk

$46.32

-13.46 (-22.52%)

At Close: Jul 31, 2026

Veracyte Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.43. In total, the insiders bought 1.13M and sold 576.47K VCYT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.43
● Buy	1.13M shares
● Sell	576.47K shares
35% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Jun 04, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -64.43. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 02, 2026 Sell	Common Stock S-Sale	Febbo Phillip G. Chief Scientific & Med Officer	Officer	13 425 Value: $485.4K
Mar 02, 2026 Sell	Common Stock F-InKind	Febbo Phillip G. Chief Scientific & Med Officer	Officer	6 035 Value: $217.3K
Mar 02, 2026 Sell	Common Stock F-InKind	Leite John Chief Commercial Officer-clia	Officer	7 517 Value: $270.7K
Mar 02, 2026 Sell	Common Stock F-InKind	Chambers Rebecca Chief Financial Officer	C-Suite Officer	7 234 Value: $260.5K
Mar 02, 2026 Sell	Common Stock F-InKind	Mcguire Annie SVP, General Counsel	Officer	6 902 Value: $248.5K
Mar 02, 2026 Sell	Common Stock F-InKind	Wygant Jonathan Vp, Chief Accounting Officer	Officer	3 006 Value: $108.2K
Feb 26, 2026 Sell	Common Stock F-InKind	Mcguire Annie SVP, General Counsel	Officer	10 867 Value: $421.1K
Feb 26, 2026 Buy	Common Stock A-Award	Mcguire Annie SVP, General Counsel	Officer	50 999 Value: $1.97M
Feb 26, 2026 Sell	Common Stock F-InKind	Febbo Phillip G. Chief Scientific & Med Officer	Officer	24 486 Value: $948.8K
Feb 26, 2026 Sell	Common Stock F-InKind	Chambers Rebecca Chief Financial Officer	C-Suite Officer	12 049 Value: $466.9K
Feb 26, 2026 Buy	Common Stock A-Award	Chambers Rebecca Chief Financial Officer	C-Suite Officer	59 324 Value: $2.30M
Feb 26, 2026 Sell	Common Stock F-InKind	Stapley Marc Chief Executive Officer	CEO / President	35 841 Value: $1.39M
Feb 26, 2026 Buy	Common Stock A-Award	Stapley Marc Chief Executive Officer	CEO / President	139 074 Value: $5.38M
Feb 26, 2026 Sell	Common Stock F-InKind	Leite John Chief Commercial Officer-clia	Officer	8 905 Value: $345.1K
Feb 26, 2026 Buy	Common Stock A-Award	Leite John Chief Commercial Officer-clia	Officer	47 149 Value: $1.83M
Feb 26, 2026 Buy	Common Stock A-Award	Febbo Phillip G. Chief Scientific & Med Officer	Officer	71 806 Value: $2.78M
Dec 16, 2025 Sell	Common Stock S-Sale	Mcguire Annie SVP, General Counsel	Officer	100 Value: $4K
Dec 16, 2025 Sell	Common Stock S-Sale	Mcguire Annie SVP, General Counsel	Officer	10 639 Value: $458.8K
Dec 05, 2025 Buy	Common Stock M-Exempt	Eastham Karin Director	Director	10 000 Value: $79.4K
Dec 05, 2025 Sell	Common Stock S-Sale	Eastham Karin Director	Director	6 392 Value: $284.6K
Dec 05, 2025 Buy	Common Stock M-Exempt	Eastham Karin Director	Director	10 000 Value: $76.0K
Dec 05, 2025 Sell	Common Stock S-Sale	Eastham Karin Director	Director	12 808 Value: $587.1K
Dec 05, 2025 Sell	Common Stock S-Sale	Eastham Karin Director	Director	800 Value: $37.3K
Dec 05, 2025 Buy	Stock Option (right to buy) M-Exempt	Eastham Karin Director	Director	10 000 Value: $79.4K
Dec 05, 2025 Buy	Stock Option (right to buy) M-Exempt	Eastham Karin Director	Director	10 000 Value: $76.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VERACYTE

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...

Read Full Profile Here